Study guide
2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection
NCC Inpatient Obstetric Nursing RNC-OB
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: Introduction & How to Use This Guide
0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology
2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions
1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders
3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders
2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications
4 Chapter 3: Antenatal Fetal Assessment & Surveillance
3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation
5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)
4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support
5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices
7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia
6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia
8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures
7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation
9 Chapter 8: Obstetric Emergencies & Critical Care
8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis
10 Chapter 9: Postpartum Physiology & Immediate Recovery Care
9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety
11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications
10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety
12 Chapter 11: Newborn Care, Transition & Clinical Assessment
11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants
13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management
12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)
14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement
13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines
2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection
Key Takeaways Explain This Topic AI
Preterm labor (PTL) is clinically defined by regular uterine contractions (≥4 in 20 minutes or ≥8 in 60 minutes) accompanied by documented cervical effacement (≥80%) or cervical dilation (≥2–3 cm) between 20 0/7 and 36 6/7 weeks of gestation.
Fetal fibronectin (fFN) testing between 22 0/7 and 34 6/7 weeks has a negative predictive value >95% to 99% for delivery within 7 to 14 days when the result is <50 ng/mL, helping prevent unnecessary hospital admissions and tocolysis.
Antenatal corticosteroids (Betamethasone 12 mg IM q24h x 2 doses OR Dexamethasone 6 mg IM q12h x 4 doses) are indicated between 24 0/7 and 33 6/7 weeks (and 34 0/7 to 36 6/7 weeks under ALPS criteria) to accelerate surfactant production and reduce neonatal RDS, IVH, NEC, and mortality.
Intravenous magnesium sulfate is administered for fetal neuroprotection between 24 0/7 and 31 6/7 weeks when preterm birth is imminent (<24 hours) to significantly reduce the incidence and severity of cerebral palsy.
Indomethacin tocolysis is strictly restricted to gestations <32 0/7 weeks for a maximum duration of 48 hours to avoid in utero constriction of the ductus arteriosus, pulmonary hypertension, and oligohydramnios.
Last updated: August 2026
Definition, Epidemiology & Risk Stratification
Preterm birth (PTB) —defined as delivery occurring between 20 0/7 and 36 6/7 weeks of gestation —is the leading cause of neonatal morbidity and mortality in non-anomalous infants. Inpatient obstetric nurses must rapidly differentiate true progressive preterm labor from benign uterine irritability to prevent inappropriate interventions while ensuring timely administration of fetal rescue bundles.
- Clinical Diagnostic Criteria for Preterm Labor
- Regular uterine contractions: ≥ 4 \ge 4 ≥ 4 contractions every 20 minutes or ≥ 8 \ge 8 ≥ 8 in 60 minutes; AND
Documented cervical change: Cervical effacement ≥ 80 % \ge 80\% ≥ 80% or cervical dilation ≥ 2 – 3 cm \ge 2\text{--}3\text{ cm} ≥ 2 – 3 cm , or progressive cervical dilation/effacement on serial clinical examinations.
Major Risk Factors for Spontaneous Preterm Birth
Prior Spontaneous Preterm Birth: The single most powerful clinical predictor. A history of one prior preterm birth confers a 1.5- to 2-fold increased risk; two prior preterm deliveries increase the risk more than 3-fold.
Short Cervical Length on Ultrasound: Transvaginal ultrasound (TVUS) cervical length <25 mm prior to 24 weeks of gestation.
Multifetal Gestation: Uterine overdistention triggers accelerated myometrial stretch, early gap junction formation, and premature oxytocin receptor upregulation.
Infection & Inflammation: Subclinical intra-amniotic infection (chorioamnionitis), bacterial vaginosis, pyelonephritis, or systemic maternal infections triggering pro-inflammatory cytokine release (IL-1, IL-6, TNF-alpha) and downstream prostaglandin cascades.
Cervical Surgical Procedures: Prior loop electrosurgical excision procedure (LEEP) or cold-knife cone biopsy.
Short Interpregnancy Interval: Interpregnancy interval <6 to 18 months .
Demographic & Nutritional Factors: Maternal pre-pregnancy BMI <19.8, maternal smoking, substance use, and severe maternal psychological stress.
Diagnostic Evaluation: TVUS Cervical Length & Fetal Fibronectin (fFN)
Accurate diagnosis prevents unnecessary maternal hospital admissions, unneeded tocolysis exposure, and unwarranted medical transfers. [ SUSPECTED PRETERM LABOR WORKUP (22 0/7 – 34 6/7 WKS) ]
- │
- ┌──────────────────────┴──────────────────────┐
- ▼ ▼
- [ Speculum Examination First ] [ Transvaginal Ultrasound ]
Collect fFN swab BEFORE digital exam Measure Cervical Length (CL):
- or lubricant; check ROM / infection • CL >30 mm: Low risk (PTL unlikely)
- │ • CL <20 mm: High risk (treat PTL)
- │ • CL 20–29 mm: Rely on fFN result
- └──────────────────────┬──────────────────────┘
- │
- ▼
- [ fFN Test Interpretation ]
- │
- ┌──────────────────────────┴──────────────────────────┐
- ▼ ▼
- [ Negative fFN (<50 ng/mL) ] [ Positive fFN (≥50 ng/mL) ]
- >95% to 99% Negative Predictive Value • Low Positive Predictive Value (~20–30%)
- Patient will NOT deliver in next 7–14 days • Increased risk of imminent preterm delivery
- Avoid unnecessary tocolytics / admission • Administer antenatal steroids & MgSO4 (if <32w)
- Fetal Fibronectin (fFN) Testing Protocols
Biomarker Concept: Fetal fibronectin is an extracellular matrix glycoprotein acting as the "biological glue" between the fetal chorion and maternal decidua. It is normally present in cervicovaginal secretions prior to 20 weeks and again near term (>35 weeks). Its presence between 22 0/7 and 34 6/7 weeks indicates mechanical or inflammatory disruption of the choriodecidual interface.
Negative Predictive Value (NPV): A negative test ( <50 ng/mL ) has an exceptional NPV of >95% to 99% for delivery within the subsequent 7 to 14 days . This provides high clinical confidence to withhold tocolytics, avoid hospital admission, and safely discharge the patient.
Positive Predictive Value (PPV): A positive test ( ≥50 ng/mL ) has a low PPV (~20% to 30%), indicating increased risk but not guaranteeing labor.
Confounders Producing False-Positive Results:
- Digital vaginal examination within the preceding 24 hours
- Sexual intercourse within the preceding 24 hours
- Moderate to gross vaginal bleeding (maternal fibronectin in blood)
- Rupture of amniotic membranes
- Endocervical lubricants, douches, or active vaginal infections
- Antenatal Corticosteroid Therapy
Antenatal corticosteroids stimulate fetal lung maturation by accelerating the synthesis and release of alveolar surfactant by type II pneumocytes, improving pulmonary compliance, and reducing microvascular permeability in the fetal brain and gastrointestinal tract.
- Evidence-Based Clinical Benefits
- Decreases Neonatal Mortality by ~31%
- Decreases Respiratory Distress Syndrome (RDS) by ~34%
- Decreases Intraventricular Hemorrhage (IVH) by ~47%
- Decreases Necrotizing Enterocolitis (NEC) by ~54%
- Dosing Regimens & Gestational Windows
Regimen Medication & Dosage Administration Route Clinical Windows & Indications
Betamethasone 12 mg IM every 24 hours for 2 doses (total 24 mg) Intramuscular (deep gluteal/ventrogluteal) 24 0/7 to 33 6/7 weeks: Standard indication for all pregnant individuals at high risk of preterm delivery within 7 days. (Considered at 22 0/7–23 6/7 weeks if active resuscitation planned).
Dexamethasone 6 mg IM every 12 hours for 4 doses (total 24 mg) Intramuscular Alternative first-line steroid regimen when Betamethasone is unavailable.
Late Preterm Steroids (ALPS) Betamethasone 12 mg IM q24h x 2 doses Intramuscular 34 0/7 to 36 6/7 weeks: For individuals at high risk of delivery within 7 days who have not received a prior course. Reduces transient tachypnea (TTN) and severe respiratory morbidity.
Rescue / Booster Course Single course of Betamethasone (12 mg IM q24h x 2) Intramuscular Indicated if initial course was given >7 to 14 days prior, patient is still <34 0/7 weeks , and delivery is again imminent within 7 days. Multiple routine courses (>2) are contraindicated due to risk of microcephaly and growth restriction.
Clinical Pearl: Antenatal corticosteroids cause transient maternal hyperglycemia (requiring intensified blood glucose surveillance and insulin titration in diabetic patients) and a temporary decrease in fetal heart rate baseline variability and biophysical profile scores lasting 48 to 72 hours post-administration.
Fetal Neuroprotection: Magnesium Sulfate ( M g S O 4 MgSO_4 M g S O 4 )
Clinical Objective: Significantly reduces the incidence and severity of cerebral palsy (CP) and gross motor dysfunction in surviving preterm infants when administered prior to imminent preterm birth.
Gestational Age Indication: Administered between 24 0/7 and 31 6/7 weeks of gestation when birth is anticipated or planned within the next 24 hours (e.g., active labor with cervical dilation ≥ 4 cm \ge 4\text{ cm} ≥ 4 cm , planned indicated preterm delivery, or PPROM with regular uterine contractions).
Standard Neuroprotective Dosing:
Loading Dose: 4 to 6 g IV over 20 to 30 minutes.
Maintenance Infusion: 1 to 2 g/hr IV continuous infusion.
Duration: Continued until delivery or for up to a maximum of 24 hours . If delivery does not occur within 24 hours and is no longer imminent, the infusion is discontinued.
Magnesium Sulfate Toxicity & Nursing Surveillance Protocol
Magnesium is eliminated almost entirely by maternal renal excretion. Impaired renal clearance causes rapid toxic accumulation. [ SERUM MAGNESIUM LEVEL & CLINICAL TOXICITY ]
- 4.8 – 8.4 mg/dL ██████████████████████████████ [ THERAPEUTIC RANGE ]
- (4.0 – 7.0 mEq/L)
- 9.6 – 12.0 mg/dL ████████████████████████████████████ [ LOSS OF PATELLAR DTRs ]
- (8.0 – 10.0 mEq/L) *Earliest clinical sign of toxicity*
- 12.0 – 14.4 mg/dL ██████████████████████████████████████████ [ RESPIRATORY DEPRESSION ]
- (10.0 – 12.0 mEq/L) *RR <12 breaths/min*
- >15.0 – 18.0 mg/dL ████████████████████████████████████████████████ [ RESPIRATORY ARREST ]
- (>12.5 mEq/L)
- >20.0 – 25.0 mg/dL ██████████████████████████████████████████████████████ [ CARDIAC ARREST ]
- (>17.0 mEq/L)
Hourly Nursing Assessments:
Patellar Deep Tendon Reflexes (DTRs): Must be present (+2 normal). Loss of DTRs is the primary early warning sign of impending severe toxicity.
Respiratory Rate: Must remain ≥ 12 breaths/min \ge 12\text{ breaths/min} ≥ 12 breaths/min with continuous pulse oximetry.
Strict Urine Output: Monitored via indwelling Foley catheter; must be ≥ 30 mL/hr \ge 30\text{ mL/hr} ≥ 30 mL/hr (or ≥ 100 mL \ge 100\text{ mL} ≥ 100 mL every 4 hours).
Emergency Antidote: Calcium Gluconate 1 g IV ( 10 mL 10\text{ mL} 10 mL of a 10 % 10\% 10% solution) administered slowly IV push over 3 to 5 minutes for severe toxicity (respiratory depression, somnolence, cardiac arrhythmias).
Tocolytic Pharmacotherapy
The primary clinical purpose of tocolytic therapy is short-term prolongation of pregnancy (up to 48 hours) to allow:
- Completion of a full course of antenatal corticosteroids;
- Administration of magnesium sulfate for neuroprotection; and
Maternal transport to a tertiary perinatal center with a Level III/IV NICU.
Tocolytics do not directly reduce neonatal mortality and are not indicated for prolonged maintenance.
Tocolytic Class & Drug Dosing Protocol Mechanism of Action Maternal Adverse Effects & Contraindications Fetal / Neonatal Considerations
Calcium Channel Blocker: ; Nifedipine (Procardia) Loading: 20–30 mg PO;; Maintenance: 10–20 mg PO q4–6h (max 180 mg/day) up to 48h Inhibits calcium influx into myometrial smooth muscle cells Maternal hypotension, reflex tachycardia, flushing, headache, dizziness.; Contraindications: Maternal hypotension (SBP <90 mmHg), severe aortic stenosis. Caution with MgSO4 (hypotension). Excellent fetal safety profile; no significant adverse fetal hemodynamic effects.
NSAID / COX Inhibitor: ; Indomethacin (Indocin) Loading: 50–100 mg PO/PR;; Maintenance: 25–50 mg PO q4–6h for maximum 48 hours Non-selective COX inhibitor; suppresses prostaglandin synthesis Gastritis, peptic ulceration, platelet dysfunction, maternal renal impairment.; Contraindications: Active peptic ulcer disease, renal disease, platelet disorders. RESTRICTED TO <32 0/7 WEEKS. ; Risks after 48h or >32w: In utero premature closure/constriction of ductus arteriosus, oligohydramnios (decreased fetal renal perfusion), NEC, IVH.
Beta-2 Agonist: ; Terbutaline (Brethine) 0.25 mg SC every 20–30 min x up to 3 doses Stimulates beta-2 receptors, increasing intracellular cAMP and relaxing myometrium Maternal tachycardia, palpitations, tremors, hypokalemia, hyperglycemia, pulmonary edema.; Contraindications: Maternal cardiac disease, uncontrolled hyperthyroidism/diabetes. Fetal tachycardia, neonatal hypoglycemia (rebound hyperinsulinism).; FDA Black Box Warning: Avoid prolonged parenteral or oral use (>48–72h).
Surgical Interventions: Cervical Cerclage
Cervical cerclage involves placing a purse-string non-absorbable suture around the cervix to provide mechanical support at the level of the internal os.
History-Indicated Cerclage: Placed electively at 12 to 14 weeks of gestation for individuals with a classic history of cervical insufficiency ( ≥ 1 \ge 1 ≥ 1 second-trimester loss characterized by painless cervical dilation in the absence of labor or placental abruption).
Ultrasound-Indicated Cerclage: Placed between 16 0/7 and 23 6/7 weeks in a singleton pregnancy with a history of prior spontaneous preterm birth and current TVUS cervical length <25 mm .
Physical Exam-Indicated (Rescue / Emergent) Cerclage: Placed when painless cervical dilation (1 to 4 cm) is discovered on sterile speculum/digital exam between 16 0/7 and 23 6/7 weeks in the absence of active labor, chorioamnionitis, or placental abruption.
Cerclage Removal Timing: Electively removed at 36 0/7 to 37 0/7 weeks in the outpatient setting, or removed immediately upon the onset of active labor, suspected chorioamnionitis, or heavy vaginal bleeding to prevent catastrophic cervical laceration or uterine rupture.